Cumulus Oncology eyes new hires and US office opening in 2021

Drug discovery accelerator Cumulus Oncology is eyeing global alliances, venture capital partnerships and a US office opening in 2021.

Co-founder and chief executive Clare Wareing said she is looking at growth opportunities in Europe and Asia, as well as adding two more newco subsidiaries and some more senior team appointments.

Edinburgh-headquartered Cumulus was founded in 2017 to create spin-out companies around novel anti-cancer therapies that are fast-tracked through development and target cancers that don’t respond well to existing treatments.

It secured a £1.7m investment round led by Eos Advisory last July and in September founded its first spin-out, Modulus Oncology, alongside the University of Sheffield.

Read more HERE.